How does maximizing shareholder value distort drug development?

episode

Medicine and Science from The BMJ not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Chris Hipkins: Labour Leader on their policy costings in the wake of PREFU, Adrian Rurawhe's death 10 min · 29 Sep 2026 · The Mike Hosking Breakfast

Nobody Knows What A Coincidence Is 36 min · 29 Sep 2026 · Toni and Ryan

NEW Nancy Guthrie Note?! Teresa Giudice Breaks Her Silence on Milania + Lindsay Clancy INNOCENT?! 52 min · 29 Sep 2026 · No Filter With Zack Peter

NPR News: 09-29-2026 2PM EDT 5 min · 29 Sep 2026 · NPR News Now

2PM ET 09/29/2026 Newscast 3 min · 29 Sep 2026 · Fox News Hourly Update

Deebo & Joe - Part 1: Reaction to Bears Beating Eagles + Maurkice Pouncey Joins 1h 4m · 29 Sep 2026 · Club Shay Shay

Report any issue

Source

Recorded28 Jul 2016

Publisherfeed.podbean.com ↗

Handlerec:13498506

Show notes

With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago. However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment. Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale. Read the full analysis: http://www.bmj.com/content/354/bmj.i3718

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in